GET DAILY SIGNALSEditas Medicine (EDIT): Evaluating the Path to $4.80 for +75% Upside
Key Takeaways
- The $4.80 central target is the arithmetic mean of eight recent, individually attributed analyst price targets, not a single firm's forecast.
- At a latest price of about $2.75, reaching $4.80 would require roughly 75% upside—a very large move.
- Recent attributable targets cluster in a $3.00 to $6.00 range, though broader tracker data extend from about $1.00 to $15.00, underscoring wide disagreement.
- Supporting factors include the CRISPR pipeline, reni-cel clinical progress, and recent upgrades from Wells Fargo, Guggenheim, and Ladenburg Thalmann.
- The biggest risks are binary clinical-trial outcomes, ongoing cash burn, and competition in sickle cell and beta-thalassemia.
- Explore Major News, Today's Price Move, Forecast, and Earnings pages for deeper data on EDIT.
- Discover Trending AI Robots to monitor changing market signals across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
This analysis reviewed eight recent, individually attributed price targets. The cluster runs from a low of $3.00 (Barclays) to a high of $6.00 (Wells Fargo, Baird, and Ladenburg Thalmann), with HC Wainwright and Guggenheim at $5.00, RBC Capital at $4.00, and Chardan Capital at $3.50. The calculated mean is approximately $4.81, rounded to a central target of $4.80. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
It is important to note that third-party trackers report a wider spectrum—some as low as $1.00 and as high as $15.00—reflecting older reports and outlier views, while aggregator consensus figures range from roughly $5.50 to $6.10. The dispersion illustrates how much analysts disagree. Optimistic views emphasize reni-cel's potential and recent positive regulatory or data developments, while cautious analysts focus on execution risk and limited near-term revenue. Recent revisions have been favorable: Wells Fargo upgraded the stock to Overweight with a $6.00 target in October 2026, Guggenheim moved to Buy at $5.00 in September 2026, and Ladenburg initiated coverage at $6.00 in August 2026.
Current Market Position and Path Toward the Target
EDIT traded near $2.75 as of early November 2026, giving the company a market capitalization of roughly $423 million. Its 52-week range spans from about $1.66 to $3.94. Reaching the $4.80 central target implies an upside of about 75%, which is a very large move and would require the shares to first clear their 52-week high near $3.94 and then extend well beyond it.
That path is plausible only with meaningful clinical or regulatory catalysts. As a clinical-stage, largely pre-revenue business, Editas generates modest collaboration income while reporting significant net losses, with losses narrowing year over year. Valuation is driven primarily by the perceived probability of success for reni-cel rather than current fundamentals, so share-price moves tend to be sharp and news-driven rather than gradual.
What Could Support a Move Toward the Target
Several verified factors could support a climb toward $4.80. Editas's reni-cel program addresses two well-understood blood disorders with clear unmet need, and the company has reported clinical data suggesting durable benefit potential. Recent analyst upgrades from Wells Fargo, Guggenheim, and Ladenburg Thalmann reflect growing confidence in the program's trajectory and a more constructive view of the company's strategic position. A shrinking net loss and a leaner operating focus have also improved the financial narrative, while broader investor appetite for gene-editing and precision-medicine assets can lift sentiment across the sector.
What Could Prevent the Target From Being Reached
The principal obstacles are clinical and financial. A disappointing data readout or a regulatory setback for reni-cel could quickly reset expectations and pressure the stock, given its binary risk profile. Editas continues to consume cash, and future financing could dilute existing shareholders. Competition in sickle cell disease and beta-thalassemia is intensifying, with other CRISPR and gene-therapy developers advancing rival treatments. Finally, because the shares remain far below their historical highs, investor skepticism and valuation compression for pre-revenue biotech names could cap upside even if the science progresses.
Technical Levels and Market Structure
Technically, the stock faces its nearest meaningful resistance at its 52-week high near $3.94, a level it has not decisively cleared. A sustained move above that area would open the way toward the psychological $4.00 and $5.00 zones before the $4.80 target comes into focus. On the downside, support has formed around the $2.40 to $2.50 area in recent trading, with the $1.66 52-week low marking the broader floor. The long-term trend remains depressed relative to the stock's multi-year history, so the chart does not yet confirm a durable reversal toward the target.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may apply different assumptions about clinical timelines and financing. Investors should monitor reni-cel clinical updates and any regulatory interactions, quarterly earnings and cash-burn trends, analyst rating and target revisions, and announcements around pipeline expansion or partnerships. Sector-wide sentiment toward gene-editing stocks and broader biotech financing conditions will also influence whether the shares can sustain a move toward $4.80.
Using AI Signals for Biotech Names
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name like Editas Medicine, these signals can help traders spot shifting momentum and identify entry or exit opportunities more efficiently than manual screening. The tool is designed to support discovery, position monitoring, and trend recognition across a broad universe of securities.
Final Assessment
The $4.80 central target represents the average of eight recent, individually attributed analyst price targets and sits well above the stock's current level near $2.75, implying a roughly 75% gain. The bull case rests on reni-cel's clinical progress and a wave of recent upgrades, while the bear case centers on binary trial risk, cash burn, and intensifying competition. With targets spanning $3.00 to $6.00—and broader tracker data stretching from $1.00 to $15.00—analysts remain sharply divided. Whether EDIT reaches $4.80 will ultimately hinge on clinical and regulatory execution rather than near-term earnings, and no outcome is guaranteed.
Exploring AI Tools for My Research
In my own process, I regularly rely on Tickeron’s AI Daily Buy/Sell Signals to stay on top of momentum shifts in names like EDIT. The platform scans thousands of securities in real time and highlights potential entry or exit points based on technical and market data, which helps me cross-check analyst views with automated signals. It has become a useful complement when evaluating clinical-stage biotech stocks where news flow can move prices quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EDIT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology
Advertisement